Open AccessSuccessful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection
Author(s) -
Jennifer Grant,
Claudia Hawkins,
Hannah Brooks,
Frank J. Palella,
Sean Koppe,
Michaël Abécassis,
Valentina Stosor
Publication year - 2016
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000000887
Subject(s) - medicine , sofosbuvir , simeprevir , hepatitis c , ribavirin , adverse effect , hepatitis c virus , population , context (archaeology) , cohort , immunology , virus , paleontology , environmental health , biology
Recurrent hepatitis C virus (HCV) infection contributes to unfavourable outcomes in HIV/HCV coinfected liver transplant recipients. Direct-acting antiviral (DAA) therapies for HCV offer an opportunity to improve patient and allograft survival in this patient population. We evaluated treatment outcomes with sofosbuvir (SOF)-based DAA therapy among HIV/HCV coinfected liver transplant recipients.